These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 30981744

  • 1. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [Abstract] [Full Text] [Related]

  • 2. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, McMurray JJV, Pfeffer MA, Solomon SD.
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [Abstract] [Full Text] [Related]

  • 3. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.
    J Am Coll Cardiol; 2019 Aug 06; 74(5):601-612. PubMed ID: 31370950
    [Abstract] [Full Text] [Related]

  • 4. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T, Ueyama H, Fujisaki T, Briasouli A, Takagi H, Briasoulis A.
    Am J Cardiol; 2020 Apr 15; 125(8):1187-1193. PubMed ID: 32081366
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
    Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJ.
    Eur J Heart Fail; 2016 Aug 15; 18(8):1021-31. PubMed ID: 27194023
    [Abstract] [Full Text] [Related]

  • 6. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD.
    JACC Heart Fail; 2017 Apr 15; 5(4):241-252. PubMed ID: 28359411
    [Abstract] [Full Text] [Related]

  • 7. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
    Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.
    Clin Res Cardiol; 2021 Aug 15; 110(8):1234-1248. PubMed ID: 33301080
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE.
    Circ Heart Fail; 2011 Sep 15; 4(5):569-77. PubMed ID: 21715583
    [Abstract] [Full Text] [Related]

  • 9. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators.
    J Am Coll Cardiol; 2019 Dec 10; 74(23):2858-2873. PubMed ID: 31806129
    [Abstract] [Full Text] [Related]

  • 10. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M, Sweitzer NK, Lindenfeld J, Kao DP.
    JACC Heart Fail; 2019 Mar 10; 7(3):228-238. PubMed ID: 30819379
    [Abstract] [Full Text] [Related]

  • 11. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
    Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ.
    Circulation; 2015 Jan 06; 131(1):43-53. PubMed ID: 25406306
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD.
    Circulation; 2015 Aug 04; 132(5):402-14. PubMed ID: 26130119
    [Abstract] [Full Text] [Related]

  • 13. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ, I-Preserve Committees and Investigators.
    Eur J Heart Fail; 2014 Jul 04; 16(7):778-87. PubMed ID: 24864045
    [Abstract] [Full Text] [Related]

  • 14. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE.
    Circ Heart Fail; 2011 May 04; 4(3):324-31. PubMed ID: 21350053
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM.
    Circ Heart Fail; 2016 Apr 04; 9(4):e002763. PubMed ID: 27056882
    [Abstract] [Full Text] [Related]

  • 16. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M.
    JAMA Netw Open; 2019 Dec 02; 2(12):e1916598. PubMed ID: 31800067
    [Abstract] [Full Text] [Related]

  • 17. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Biering-Sørensen T, Shah SJ, Anand I, Sweitzer N, Claggett B, Liu L, Pitt B, Pfeffer MA, Solomon SD, Shah AM.
    Eur J Heart Fail; 2017 Aug 02; 19(8):1043-1052. PubMed ID: 28322009
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
    Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM.
    Circ Heart Fail; 2011 Jan 02; 4(1):27-35. PubMed ID: 21068341
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B.
    JACC Heart Fail; 2015 Jun 02; 3(6):429-441. PubMed ID: 25982110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.